von Willebrand factor can interact with osteoprotegrin to regulate osteoclast differentiation [82], and a transgenic GP1BA von Willebrand disease model has increased bone mass and reduced osteoclast activity [83]. This evidence concerns the gene VWF and Von Willebrand disease.